Enviar búsqueda
Cargar
lecture1_2008_p734
•
Descargar como PPT, PDF
•
1 recomendación
•
542 vistas
Flavio Guzmán
Seguir
Tecnología
Empresariales
Denunciar
Compartir
Denunciar
Compartir
1 de 33
Descargar ahora
Recomendados
Personalized Medicine Overview
Personalized Medicine Overview
ahelicher
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Career Development Service, University of Leicester
Personalized medicine
Personalized medicine
Mehak AggarwAl
Pharmacogenomics as a tool for Personalized medicine
Pharmacogenomics as a tool for Personalized medicine
PharmCare Research Group USM
Personalized medicine - Mathura Shanmugasundaram PhD
Personalized medicine - Mathura Shanmugasundaram PhD
Mathura Shanmugasundaram PhD
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
Mathura Shanmugasundaram PhD
Consensus or Controversy Should Mutational Analysis (Ma) Be Considered as a R...
Consensus or Controversy Should Mutational Analysis (Ma) Be Considered as a R...
CrimsonpublishersCancer
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
F. Cankat Tulunay
Recomendados
Personalized Medicine Overview
Personalized Medicine Overview
ahelicher
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Developing a Test to Predict Side Effects of Chemotherapy in Patients with Co...
Career Development Service, University of Leicester
Personalized medicine
Personalized medicine
Mehak AggarwAl
Pharmacogenomics as a tool for Personalized medicine
Pharmacogenomics as a tool for Personalized medicine
PharmCare Research Group USM
Personalized medicine - Mathura Shanmugasundaram PhD
Personalized medicine - Mathura Shanmugasundaram PhD
Mathura Shanmugasundaram PhD
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
The case for Genomic Medicine, (Personalized, Individualized Medicine). Medic...
Mathura Shanmugasundaram PhD
Consensus or Controversy Should Mutational Analysis (Ma) Be Considered as a R...
Consensus or Controversy Should Mutational Analysis (Ma) Be Considered as a R...
CrimsonpublishersCancer
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
ONCOPHARMACOECONOMY-I, Prof. Dr. F. Cankat Tulunay
F. Cankat Tulunay
Personalised Medicine
Personalised Medicine
PharmCare Research Group USM
Pharmacogenetic Flyer
Pharmacogenetic Flyer
April Carrillo
Metronomic Chemotherapy
Metronomic Chemotherapy
Sonali Karekar
Personalized Medicine
Personalized Medicine
Medavie Blue Cross
Comparative evaluation between Quality of life (Qol), Adverse events and Surv...
Comparative evaluation between Quality of life (Qol), Adverse events and Surv...
Sandeep Roy
12 Dr. Thomas Schreitmueller Roche
12 Dr. Thomas Schreitmueller Roche
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Oafp 06 2009 Ra
Oafp 06 2009 Ra
LawrenceJacobs
Personalized medicine
Personalized medicine
Peter Egorov
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Pranav Sopory
Petrulli_SNM_2014_Talk
Petrulli_SNM_2014_Talk
Joseph Petrulli
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Towards Personalized Medicine
Towards Personalized Medicine
Michel Dumontier
A common rejection module (CRM) for acute rejection across multiple organs
A common rejection module (CRM) for acute rejection across multiple organs
Kevin Jaglinski
Personalized Medicine: Current and Future Perspectives Personalized Medicin...
Personalized Medicine: Current and Future Perspectives Personalized Medicin...
MedicineAndHealth
Personalized medicine ppt
Personalized medicine ppt
Irene Daniel
Personalized Medicine
Personalized Medicine
Dalia A. Hamdy
Aung thiha soe
Aung thiha soe
zawhtet1984
2013-04-17: The Promise, Current State, And Future of Personalized Medicine
2013-04-17: The Promise, Current State, And Future of Personalized Medicine
Baltimore Lean Startup
BPS Pharmacology 2016 Meeting - Albert Antolin
BPS Pharmacology 2016 Meeting - Albert Antolin
Albert A. Antolín Hernández
The-Case-for-Practice-Integration[1]
The-Case-for-Practice-Integration[1]
Amy Williams
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Zohaib HUSSAIN
Demystifying Pharmacogenetics
Demystifying Pharmacogenetics
TELUS Health | TELUS Santé
Más contenido relacionado
La actualidad más candente
Personalised Medicine
Personalised Medicine
PharmCare Research Group USM
Pharmacogenetic Flyer
Pharmacogenetic Flyer
April Carrillo
Metronomic Chemotherapy
Metronomic Chemotherapy
Sonali Karekar
Personalized Medicine
Personalized Medicine
Medavie Blue Cross
Comparative evaluation between Quality of life (Qol), Adverse events and Surv...
Comparative evaluation between Quality of life (Qol), Adverse events and Surv...
Sandeep Roy
12 Dr. Thomas Schreitmueller Roche
12 Dr. Thomas Schreitmueller Roche
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Oafp 06 2009 Ra
Oafp 06 2009 Ra
LawrenceJacobs
Personalized medicine
Personalized medicine
Peter Egorov
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Pranav Sopory
Petrulli_SNM_2014_Talk
Petrulli_SNM_2014_Talk
Joseph Petrulli
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
Towards Personalized Medicine
Towards Personalized Medicine
Michel Dumontier
A common rejection module (CRM) for acute rejection across multiple organs
A common rejection module (CRM) for acute rejection across multiple organs
Kevin Jaglinski
Personalized Medicine: Current and Future Perspectives Personalized Medicin...
Personalized Medicine: Current and Future Perspectives Personalized Medicin...
MedicineAndHealth
Personalized medicine ppt
Personalized medicine ppt
Irene Daniel
Personalized Medicine
Personalized Medicine
Dalia A. Hamdy
Aung thiha soe
Aung thiha soe
zawhtet1984
2013-04-17: The Promise, Current State, And Future of Personalized Medicine
2013-04-17: The Promise, Current State, And Future of Personalized Medicine
Baltimore Lean Startup
BPS Pharmacology 2016 Meeting - Albert Antolin
BPS Pharmacology 2016 Meeting - Albert Antolin
Albert A. Antolín Hernández
La actualidad más candente
(19)
Personalised Medicine
Personalised Medicine
Pharmacogenetic Flyer
Pharmacogenetic Flyer
Metronomic Chemotherapy
Metronomic Chemotherapy
Personalized Medicine
Personalized Medicine
Comparative evaluation between Quality of life (Qol), Adverse events and Surv...
Comparative evaluation between Quality of life (Qol), Adverse events and Surv...
12 Dr. Thomas Schreitmueller Roche
12 Dr. Thomas Schreitmueller Roche
Oafp 06 2009 Ra
Oafp 06 2009 Ra
Personalized medicine
Personalized medicine
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Metronomic Chemotherapy Vs Best Supportive Care in Progressive Pediatric Tumors.
Petrulli_SNM_2014_Talk
Petrulli_SNM_2014_Talk
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
9. Dr. Thomas Schreitmueller - F. Hoffmann-La Roche
Towards Personalized Medicine
Towards Personalized Medicine
A common rejection module (CRM) for acute rejection across multiple organs
A common rejection module (CRM) for acute rejection across multiple organs
Personalized Medicine: Current and Future Perspectives Personalized Medicin...
Personalized Medicine: Current and Future Perspectives Personalized Medicin...
Personalized medicine ppt
Personalized medicine ppt
Personalized Medicine
Personalized Medicine
Aung thiha soe
Aung thiha soe
2013-04-17: The Promise, Current State, And Future of Personalized Medicine
2013-04-17: The Promise, Current State, And Future of Personalized Medicine
BPS Pharmacology 2016 Meeting - Albert Antolin
BPS Pharmacology 2016 Meeting - Albert Antolin
Similar a lecture1_2008_p734
The-Case-for-Practice-Integration[1]
The-Case-for-Practice-Integration[1]
Amy Williams
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Zohaib HUSSAIN
Demystifying Pharmacogenetics
Demystifying Pharmacogenetics
TELUS Health | TELUS Santé
pharmacogenomicspptnsu-191212202112 (1).pptx
pharmacogenomicspptnsu-191212202112 (1).pptx
Dr. majid farooq
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
Michel Dumontier
Phrmacogentics
Phrmacogentics
Maan Singh
Ectopic pregnancy medical management wanjala 2012
Ectopic pregnancy medical management wanjala 2012
Lagendary_MD
Personalized medicine
Personalized medicine
Madiheh
Metastatic prostate cancer, nejm 2018
Metastatic prostate cancer, nejm 2018
marcela maria morinigo kober
J IAJPS Immanuels
J IAJPS Immanuels
Immanuel Jebastine M
1. Pharmacogenomics.pptx
1. Pharmacogenomics.pptx
AnandKumar279666
Pharmacology
Pharmacology
Nidhishbio
Pharmacogenomics- a step to personalized medicines
Pharmacogenomics- a step to personalized medicines
Apusi Chowdhury
Foro de genéricos y biosimilares
Foro de genéricos y biosimilares
Mauricio Lema
2014-07-17-Clarinet-results-NEJM-FINAL
2014-07-17-Clarinet-results-NEJM-FINAL
Harold Dumont
Pharmaogenomics
Pharmaogenomics
FarazaJaved
Pharmacogenomics
Pharmacogenomics
Dr Debasish Pradhan
Clinical Utility of Pharmacogenetic Testing in Compounding Pharmacy
Clinical Utility of Pharmacogenetic Testing in Compounding Pharmacy
Brian Fichter
Pharmacogenetics and Pharmacogenomics
Pharmacogenetics and Pharmacogenomics
Dr. Prashant Shukla
Queneau
Queneau
evivoudiklari
Similar a lecture1_2008_p734
(20)
The-Case-for-Practice-Integration[1]
The-Case-for-Practice-Integration[1]
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Pharmacogenomics, Pharmacogenetics and Pharmacokinetics
Demystifying Pharmacogenetics
Demystifying Pharmacogenetics
pharmacogenomicspptnsu-191212202112 (1).pptx
pharmacogenomicspptnsu-191212202112 (1).pptx
20091109 Biol1010 Personalized Medicine
20091109 Biol1010 Personalized Medicine
Phrmacogentics
Phrmacogentics
Ectopic pregnancy medical management wanjala 2012
Ectopic pregnancy medical management wanjala 2012
Personalized medicine
Personalized medicine
Metastatic prostate cancer, nejm 2018
Metastatic prostate cancer, nejm 2018
J IAJPS Immanuels
J IAJPS Immanuels
1. Pharmacogenomics.pptx
1. Pharmacogenomics.pptx
Pharmacology
Pharmacology
Pharmacogenomics- a step to personalized medicines
Pharmacogenomics- a step to personalized medicines
Foro de genéricos y biosimilares
Foro de genéricos y biosimilares
2014-07-17-Clarinet-results-NEJM-FINAL
2014-07-17-Clarinet-results-NEJM-FINAL
Pharmaogenomics
Pharmaogenomics
Pharmacogenomics
Pharmacogenomics
Clinical Utility of Pharmacogenetic Testing in Compounding Pharmacy
Clinical Utility of Pharmacogenetic Testing in Compounding Pharmacy
Pharmacogenetics and Pharmacogenomics
Pharmacogenetics and Pharmacogenomics
Queneau
Queneau
Más de Flavio Guzmán
Ops
Ops
Flavio Guzmán
Pk2
Pk2
Flavio Guzmán
Pk2
Pk2
Flavio Guzmán
Kinetika En 2002
Kinetika En 2002
Flavio Guzmán
Pk1 Ppt
Pk1 Ppt
Flavio Guzmán
Kinetika En 2002
Kinetika En 2002
Flavio Guzmán
Ceorins
Ceorins
Flavio Guzmán
AUPDATE
AUPDATE
Flavio Guzmán
05052008OvarianTelehealth
05052008OvarianTelehealth
Flavio Guzmán
mati
mati
Flavio Guzmán
DrTerespolsky
DrTerespolsky
Flavio Guzmán
15
15
Flavio Guzmán
gopalan031607
gopalan031607
Flavio Guzmán
IncidentalomaTalk
IncidentalomaTalk
Flavio Guzmán
Nikiforov
Nikiforov
Flavio Guzmán
Thpt
Thpt
Flavio Guzmán
Thyroid Disease
Thyroid Disease
Flavio Guzmán
THYCER
THYCER
Flavio Guzmán
DrRobertFoxUtahSSF
DrRobertFoxUtahSSF
Flavio Guzmán
Sjögren's_syndrome~_Role_for_Cevimeline
Sjögren's_syndrome~_Role_for_Cevimeline
Flavio Guzmán
Más de Flavio Guzmán
(20)
Ops
Ops
Pk2
Pk2
Pk2
Pk2
Kinetika En 2002
Kinetika En 2002
Pk1 Ppt
Pk1 Ppt
Kinetika En 2002
Kinetika En 2002
Ceorins
Ceorins
AUPDATE
AUPDATE
05052008OvarianTelehealth
05052008OvarianTelehealth
mati
mati
DrTerespolsky
DrTerespolsky
15
15
gopalan031607
gopalan031607
IncidentalomaTalk
IncidentalomaTalk
Nikiforov
Nikiforov
Thpt
Thpt
Thyroid Disease
Thyroid Disease
THYCER
THYCER
DrRobertFoxUtahSSF
DrRobertFoxUtahSSF
Sjögren's_syndrome~_Role_for_Cevimeline
Sjögren's_syndrome~_Role_for_Cevimeline
Último
Real Time Object Detection Using Open CV
Real Time Object Detection Using Open CV
Khem
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
Safe Software
The Role of Taxonomy and Ontology in Semantic Layers - Heather Hedden.pdf
The Role of Taxonomy and Ontology in Semantic Layers - Heather Hedden.pdf
Enterprise Knowledge
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
sudhanshuwaghmare1
Slack Application Development 101 Slides
Slack Application Development 101 Slides
praypatel2
Tata AIG General Insurance Company - Insurer Innovation Award 2024
Tata AIG General Insurance Company - Insurer Innovation Award 2024
The Digital Insurer
08448380779 Call Girls In Diplomatic Enclave Women Seeking Men
08448380779 Call Girls In Diplomatic Enclave Women Seeking Men
Delhi Call girls
Data Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt Robison
Anna Loughnan Colquhoun
GenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day Presentation
Michael W. Hawkins
How to convert PDF to text with Nanonets
How to convert PDF to text with Nanonets
naman860154
A Year of the Servo Reboot: Where Are We Now?
A Year of the Servo Reboot: Where Are We Now?
Igalia
Breaking the Kubernetes Kill Chain: Host Path Mount
Breaking the Kubernetes Kill Chain: Host Path Mount
Puma Security, LLC
Driving Behavioral Change for Information Management through Data-Driven Gree...
Driving Behavioral Change for Information Management through Data-Driven Gree...
Enterprise Knowledge
Finology Group – Insurtech Innovation Award 2024
Finology Group – Insurtech Innovation Award 2024
The Digital Insurer
Advantages of Hiring UIUX Design Service Providers for Your Business
Advantages of Hiring UIUX Design Service Providers for Your Business
Pixlogix Infotech
Strategies for Unlocking Knowledge Management in Microsoft 365 in the Copilot...
Strategies for Unlocking Knowledge Management in Microsoft 365 in the Copilot...
Drew Madelung
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
The Digital Insurer
Boost PC performance: How more available memory can improve productivity
Boost PC performance: How more available memory can improve productivity
Principled Technologies
TrustArc Webinar - Stay Ahead of US State Data Privacy Law Developments
TrustArc Webinar - Stay Ahead of US State Data Privacy Law Developments
TrustArc
Automating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps Script
wesley chun
Último
(20)
Real Time Object Detection Using Open CV
Real Time Object Detection Using Open CV
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
From Event to Action: Accelerate Your Decision Making with Real-Time Automation
The Role of Taxonomy and Ontology in Semantic Layers - Heather Hedden.pdf
The Role of Taxonomy and Ontology in Semantic Layers - Heather Hedden.pdf
Boost Fertility New Invention Ups Success Rates.pdf
Boost Fertility New Invention Ups Success Rates.pdf
Slack Application Development 101 Slides
Slack Application Development 101 Slides
Tata AIG General Insurance Company - Insurer Innovation Award 2024
Tata AIG General Insurance Company - Insurer Innovation Award 2024
08448380779 Call Girls In Diplomatic Enclave Women Seeking Men
08448380779 Call Girls In Diplomatic Enclave Women Seeking Men
Data Cloud, More than a CDP by Matt Robison
Data Cloud, More than a CDP by Matt Robison
GenCyber Cyber Security Day Presentation
GenCyber Cyber Security Day Presentation
How to convert PDF to text with Nanonets
How to convert PDF to text with Nanonets
A Year of the Servo Reboot: Where Are We Now?
A Year of the Servo Reboot: Where Are We Now?
Breaking the Kubernetes Kill Chain: Host Path Mount
Breaking the Kubernetes Kill Chain: Host Path Mount
Driving Behavioral Change for Information Management through Data-Driven Gree...
Driving Behavioral Change for Information Management through Data-Driven Gree...
Finology Group – Insurtech Innovation Award 2024
Finology Group – Insurtech Innovation Award 2024
Advantages of Hiring UIUX Design Service Providers for Your Business
Advantages of Hiring UIUX Design Service Providers for Your Business
Strategies for Unlocking Knowledge Management in Microsoft 365 in the Copilot...
Strategies for Unlocking Knowledge Management in Microsoft 365 in the Copilot...
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Bajaj Allianz Life Insurance Company - Insurer Innovation Award 2024
Boost PC performance: How more available memory can improve productivity
Boost PC performance: How more available memory can improve productivity
TrustArc Webinar - Stay Ahead of US State Data Privacy Law Developments
TrustArc Webinar - Stay Ahead of US State Data Privacy Law Developments
Automating Google Workspace (GWS) & more with Apps Script
Automating Google Workspace (GWS) & more with Apps Script
lecture1_2008_p734
1.
Principles of Pharmacogenomics
Readings: Pharmacogenomics (Rothstein,ed. Chapter 2, 8, 9, 11) ©2003-2008 Gus Rosania
2.
3.
The Simple Definition
©2003-2008 Gus Rosania Pharmacogenomics: using genetic information to predict whether a drug will help make a patient well or ill. +
4.
5.
6.
7.
8.
2. Forces Driving
Pharmacogenomics into Healthcare Practice ©2003-2008 Gus Rosania
9.
QUESTION What are
the driving forces behind pharmacogenomics?
10.
1A. Adverse drug
reaction costs insurance co. billions $$ Reasons: Prescription error, overdosing, drug interactions, population genetic variables. Drug interactions: Two or more drugs metabolized or eliminated by the same mechanism administered at same time can saturate mechanism, leading to toxicity. Adverse drug effects are estimated to be the 5 th or 6 th cause of illness and death in the US. Costs estimates range between 30 to 150 billion a year. Adverse drug effects account for up to 7% of hospitalizations in US ©2003-2008 Gus Rosania
11.
1B. Many drugs
are intrinsically unsafe and could be made safer Anticoagulants: Warfarin clots, stroke bleeding/death Anticancer: Paclitaxel Cancer grows immunocytopenia Pain killers: Morphine No effect Addiction/death Statins Lipitor high cholestrol myopathy/death Acetaminophen Tylenol No pain relief Liver failure/death Example Too little Too much ©2003-2008 Gus Rosania
12.
1C. Current dosage
strategy: bias towards low efficacy/low tox Condition Efficacy Annual Rx cost Alzheimer’s 30% $1,500 Analgesics (Cox2) 80% $1,350 Asthma 60% $ 330 Cardiac arrythmia 60% $ 650 Depression 62% $ 700 Diabetes 57% $1,300 HCV 47% $5,000 Incontinence 40% $1,000 Migraine (acute) 52% $ 240 Migraine (prophylaxis) 50% $ 600 Oncology 25% $3,500 ©2003-2008 Gus Rosania
13.
1D. The cost
of marketed drug failures Cost of developing a new drug: $500 to $700 million Time from drug patent to product launch: 12 years Time until patent expires: 7 years ©2003-2008 Gus Rosania
14.
15.
16.
Drug X Efficacy
in an Individual Patient Efficacy Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 ©2003-2008 Gus Rosania
17.
Drug X Efficacy
in Patient Population Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 ©2003-2008 Gus Rosania
18.
DoseX-%efficacy curve Dose
(mg/kg) 0 1 2 3 4 5 6 7 8 9 % Patients Cured by Drug 100 90 80 70 60 50 40 30 20 10 0 ©2003-2008 Gus Rosania
19.
Drug X Toxicity
for Individual Patient Toxicity Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 ©2003-2008 Gus Rosania
20.
Drug X Toxicity
in Patient Population Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 ©2003-2008 Gus Rosania
21.
DrugX-toxicity curve Dose
(mg/kg) 0 1 2 3 4 5 6 7 8 9 % Patients showing ADR 100 90 80 70 60 50 40 30 20 10 0 ©2003-2008 Gus Rosania
22.
Drug X combined
efficacy-toxicity curves % Patients Showing 100 90 80 70 60 50 40 30 20 10 0 Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 % Patients 100 90 80 70 60 50 40 30 20 10 0 ©2003-2008 Gus Rosania
23.
Safe drug: large
window Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Therapeutic window Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 ©2003-2008 Gus Rosania
24.
Efficacy-toxicity curves for
safe drug % Patients Showing 100 90 80 70 60 50 40 30 20 10 0 Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 % Patients Responding to drug 100 90 80 70 60 50 40 30 20 10 0 ©2003-2008 Gus Rosania
25.
Unsafe drug: small
window Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 Therapeutic window ©2003-2008 Gus Rosania
26.
Drug-Toxicity Curves for
unsafe Drug % Patients Showing 100 90 80 70 60 50 40 30 20 10 0 Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 % Patients 100 90 80 70 60 50 40 30 20 10 0 ©2003-2008 Gus Rosania
27.
28.
Use genetic info
to enhance the therapeutic index TI without PG ©2003-2008 Gus Rosania Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Dose (mg/kg) 0 1 2 3 4 5 6 7 8 9 Therapeutic index w/ PG
29.
What are the
steps for translating pharmacogenomic info. from research into practice? ©2003-2008 Gus Rosania
30.
Step 1. Identify
SNPs in genes relevant to drug efficacy or tox Human Genome: 2,900,000,000 total base pairs 10,000,000 total single nucleotide polymorphisms (SNP) 300,000 variant haplotypes 10,000 haplotypes in pharmacologically-relevant genes ©2003-2008 Gus Rosania
31.
Step 2. Retrospectively,
find SNPs associated with response Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10 Patient 11 Patient 12 Good response No response No response Good response No response No response Good response Good response Good response Good response No response No response ATGCTTCCCTTTTAAA ATTGTTCCCTTTTAAA ATTGTTGCCTTTTAAA ATGGTTGCCTTTTAAA ATAGTTGCCTTTTAAT ATAGTTGCCTTTTAAT ATGATTGCCTTTTAAA ATGATTGGCTTTTAAA ATGTTTCGCTTTTAAA ATGTTTTGCTTTTAAA ATTTTTTGCTTTTAAA ATCTTTTGCTTTTAAA SNP: single nucleotide polymorphism Good response Good response Good response Good response Good response 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 ©2003-2008 Gus Rosania
32.
Step 3. Prospectively,
determine if those SNPs affect therapeutic outcome G G G G G G G G G G G G G G G G G G G G G G G G G G Treat 25% cure 50% cure Determine statistical significance (the probability that such a difference is due to random chance) ©2003-2008 Gus Rosania
33.
Step 4. Require
physician or pharmacist to perform those tests ©2003-2008 Gus Rosania
Descargar ahora